Sweden's Camurus Q3 revenue beats estimates on Buvidal, Brixadi growth
Overview
Sweden biopharma firm's Q3 revenue rose 28% yr/yr, beating analyst expectations
Q3 operating profit grew 40% yr/yr
Company reiterated 2026 outlook, expects results in upper half of guided ranges
Outlook
Camurus expects 2026 revenues in the upper half of BNSEK 2.6-2.9 guidance range
Company sees 2026 operating result in the upper half of BNSEK 0.9-1.2 guidance range
FDA decision on CAM2029 for acromegaly expected by 18 December, 2026
Result Drivers
BUVIDAL AND BRIXADI GROWTH - Co said record product sales were driven by continued growth for Buvidal and higher Brixadi royalties
NO MILESTONE REVENUE - Co noted that Q3 results were achieved without milestone revenue contributions
REGULATORY PROGRESS - Co highlighted FDA review of CAM2029 and Australian approval of Oczyesa as key developments in the quarter
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | SEK 724 mln | SEK 691.20 mln (5 Analysts) |
Q3 EBIT | SEK 322 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Camurus AB is SEK780.00, about 17.3% above its November 4 closing price of SEK665.00
The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 29 three months ago
Reuters Recommended Reads
Nov 4 - Novo loses share in Brazil to cheaper generics, but holds up in Canada and India
Nov 4 - Novo Nordisk Q3 adjusted profit, sales jump on GLP-1 demand; raises outlook
Nov 2 - Travere Q3 product sales nearly double on FILSPARI growth
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)